ClinicalTrials.gg
RecruitingNCT07519408Updated Nov 5, 2026

Acute Kidney Injury and Ultra-endurance Running

An interventional study of Sodium Bicarbonate (NaHCO3) and Placebo in AKI (Acute Kidney Injury) Due to Trauma, sponsored by Arizona State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Arizona State University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 5, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies testing Sodium Bicarbonate in Acute Kidney Injury — 3 open to participants now, 4 under way, none of them phase 3. Sodium Bicarbonate · Acute Kidney Injury.

Planned enrollment
16th of 18
30 · median 112
Started
2026
with 1 other
No phase
6 of 18
2 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Arizona State University

Among the 18 studies testing Sodium Bicarbonate in Acute Kidney Injury, this one is the 16th largest by planned enrollment, is one of 2 that started in 2026, is one of 6 with no phase, and was the 18th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

3 of the 18 studies testing Sodium Bicarbonate in Acute Kidney Injury are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Sodium Bicarbonate

Sodium Bicarbonate: first FDA approval 1981 (BSS PLUS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Sodium Bicarbonate in Acute Kidney Injury, or all of them as a file.
02

Study summary

This study aims to understand how participating in the Western States Endurance Run (WSER), a 100-mile ultramarathon, affects kidney health. Long, strenuous exercise in hot conditions can temporarily strain the kidneys, especially when combined with dehydration, muscle breakdown, and the use of common pain-relief medications such as ibuprofen. Although kidney stress has been reported in endurance sports, no study has examined it directly in runners during the WSER using newer, more sensitive urine markers of kidney injury. Runners who volunteer will complete brief assessments before and after the race. These include providing a urine sample, a small finger-prick blood sample, a body-weight measurement, and answering a short questionnaire about pain-medication use. During the race, participants will wear a global positioning system (GPS) watch and heart-rate strap to monitor effort. Each assessment takes about 15 minutes, and no follow-up is required. Findings from this study will help determine how often kidney stress occurs in this event and what factors may contribute to it, ultimately supporting safer training and medical practices for ultramarathon athletes.

Read the detailed description

The study is a single-group, pre- and post-test design where participants will be assessed prior to the start of the WSER, upon completion of the race and 24 hours post-race. Approximately one hour prior to the race commencing, participants will be asked to void the entire contents of their bladder in a urine container in order to measure urine volume, flow rate and urine specific gravity (USG) to assess hydration status and for subsequent analysis of acute kidney injury (AKI) risk (insulin-like growth factor-binding protein 7 (IGFBP7), tissue inhibitor of metalloproteinase 2 (TIMP-2), and neutrophil gelatinase-associated lipocalin (NGAL)). Participants will also be provided a Garmin 945 GPS watch and a wearable device (i.e., the HRM-PRO Run Dynamics strap) for the race. The system is a waterproof heartrate monitor strap with an embedded accelerometer that quantifies gait metrics (ground reaction force). At this time they will also have their weight measured, and complete a short questionnaire to document any recent intake of non-steroidal anti-inflammatory (NSAIDS) medication. Lastly, the research team will collect a small capillary sample (\~ 300 microliters) of whole blood into a heparinised tube and immediately analyse the sample for creatinine (CR) and blood urea nitrogen (BUN) using a portable, point of care analyzer (i-STAT 1 Wireless, Abbott, Princeton).

Upon completing the WSER, participants will again be asked to provide a urine sample (following the pre-race methodology), have their weight measured, complete the questionnaire regarding additional NSAID use during the race, and lastly a final capillary blood sample for post-race analysis of CR and BUN. Participants will then be randomized into one of two groups (sodium bicarbonate (SB) or placebo), with one receiving a pre-packaged standard amount of either 15, 19, or 22 grams of sodium bicarbonate provided by Maurten (Maurten Bicarb System, MaurtenTM, Göteborg, SWE) depending on their body weight. MaurtenTM will also provide an equivalent placebo product. Participants will be asked to consume the SB or placebo, which is delivered in a patented hydrogel system (similar to a yogurt). The urine and blood sampling procedure will be repeated 24 hours post-race at a location to be determined.

All urine samples will be packed in an appropriately labeled biohazard container with cold packs, and brought back to the Arizona State University's Integrated Human Performance Lab (IHPL; Principle Investigator (PI)-Siegler) for measures of AKI risk with the research team. As per the Transportation Security Administration (TSA) regulations, biological specimens that are non-infectious and contain less than 30 mL of fluid in each container are permissible in checked baggage. The samples from each of the 3 races will be approximately 5 milliliters (mL) each subject (so estimated at 50 mL total for each of the 3 races).

Methodological Techniques \& Measurements:

Anthropometric Assessments (Descriptive Data) Participants will be asked to use the restroom to empty their bladder (this sample will be used for AKI biomarkers, urine volume and USG), after which measurements of height and body mass will be obtained. This measurement will occur pre- and post-race to estimate loss of body weight (e.g., dehydration).

Urine Volume and Specific Gravity (USG) Participants will be asked to void into graduated measuring containers (\~ 900 mL), which will subsequently be used to calculate total urine volume pre-, post-race, and 24 hours post-race and normalize AKI markers. Once volume is obtained, samples from this measurement will be used to assess dehydration (USG) and for subsequent analysis of AKI (see Kidney Injury Markers). USG will be measured using a handheld refractometer (Atago PALTMSeries, Tokyo, JP).

Capillary Blood Draws Capillary blood (\~ 300 microliters; 600 total) will be obtained from an index finger pre-, post-race and 24 hours post-race to measure creatinine (CR) and blood urea nitrogen (BUN) using a portable, point of care analyzer (i-STAT 1 Wireless, Abbott, Princeton).

Kidney Injury Markers AKI risk will be assessed using Enzyme-Linked Immunosorbent Assay (ELISA) kits to measure concentrations of insulin-like growth factor-binding protein 7 (IGFBP7) (RayBiotech Life, Peachtree Corners, GA), tissue inhibitor of metalloproteinase 2 (TIMP-2) (RayBiotech Life, Peachtree Corners, GA), and neutrophil gelatinase-associated lipocalin (NGAL) (Enzo Life Sciences, Farmingdale, NY). Urine samples will be centrifuged before analysis and resultant supernatant used for analyses. The kidney markers will be normalized to urine flow rate, considering changes in the urine production that may happen in dehydration conditions such as exercise in the heat. All ELISA analyses will be completed according to manufacturer guidelines.

Heart Rate and Activity Profile Participants will wear a chest-mounted heart rate monitor (Garmin HRM-PRO Run Dynamics strap) during the race. The device consists of an elastic strap with an embedded sensor that is worn directly against the skin, positioned horizontally around the chest, just below the pectoral muscles (breastbone), in accordance with manufacturer instructions. Prior to the race, a trained member of the research team will demonstrate proper placement and fit of the heart rate strap. Participants will be instructed to ensure the strap fits snugly but comfortably, allowing normal breathing and movement without excessive tightness. The strap does not deliver electrical stimulation or vibration; it passively records heart rate and movement data. Participants may adjust or remove the heart rate strap at any time during the race if they experience discomfort, skin irritation, or any other concern. Removal of the strap will not affect continued participation in the study or result in penalty. Heart rate (HR) and activity rates (via accelerometer measurements) will be measured continuously (1 hertz (Hz)) during the race with participants wearing a Garmin 945 GPS watch and a wearable device (i.e., the HRM-PRO Run Dynamics strap).

NSAID Questionnaire During the pre-race data collection period, participants will be asked if they have consumed any non-steroidal anti-inflammatory drugs prior to the start of the race (quantity and type (e.g., ibuprofen)). Once the race is completed, the same questionnaire will be used to ask participants if they consumed any NSAIDs during the race, and at what quantity.

03

Conditions studied

  • AKI (Acute Kidney Injury) Due to Trauma

Browse trials for

Keywords

  • ultra-endurance
  • bicarbonate
  • AKI
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Running in the Western States Endurance Run in either 2026, 2027 or 2028
  • No to exercise as indicated by the Physical Activity Readiness Questionnaire (PAR-Q+) as prepared by the American College of Sports Medicine (ACSM)
  • Not currently taking medicine or experiencing illness that may influence the cardiovascular or neuromuscular system
  • Age ≥18 and ≤ 50 years old and injury free (skeletal muscle) for > 3 months

Exclusion criteria

Exclusion Criteria:

  • Minors (under 18)
  • Adults who are unable to consent (impaired decision-making capacity)
  • Prisoners
  • Pregnant Women
  • Individuals with known kidney disease, or are on any medication that specifically effects kidney function (e.g., diuretics)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    sodium bicarbonate

    volunteers will be provided 0.3g/kg body weight of sodium bicarbonate to be consumed after completing the Western States Endurance Run (100 miles)

    Dietary Supplement: Sodium Bicarbonate (NaHCO3)

  • Placebo comparator
    placebo

    volunteers will be provide 0.3g/kg body weight of placebo (corn starch) to be consumed after the race.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementSodium BicarbonateStudies of Sodium BicarbonateSodium Bicarbonate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SB will be used to investigate whether adding a buffer exogenously to aid recovery helps in reducing the severity of acute kidney injury.

  • Dietary supplementPlacebo

    The placebo product consists of the same sodium concentration as the intervention group receiving sodium bicarbonate.

06

What researchers measure

Primary outcomes

  1. tissue inhibitor of metalloproteinase 2 (TIMP-2)

    urine biomarkers of acute kidney injury

    Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample

  2. neutrophil gelatinase-associated lipocalin (NGAL)

    urine biomarkers of acute kidney injury

    Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample

  3. Cystatin C

    urine biomarkers of acute kidney injury

    Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2028, 25 months after the start.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 25 months is close to that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 9, 2026
StartActual
Jun 27, 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
1 site added — first site in United States
Show site
  • ASU Health Futures Center · Phoenix, United States
Nov 5, 2026
Primary outcomes
1 edited, 2 added
What changed in the outcomes
  • ChangedBefore Insulin-like growth factor-binding protein 7 (IGFBP7), tissue inhibitor of metalloproteinase 2 (TIMP-2), and neutrophil gelatinase-associated lipocalin (NGAL)Now tissue inhibitor of metalloproteinase 2 (TIMP-2)Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample
  • Addedneutrophil gelatinase-associated lipocalin (NGAL)Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample
  • AddedCystatin CTime frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • ASU Health Futures Center · Phoenix, United States
    Primary outcomes 1 edited, 2 added
    What changed in the outcomes
    • ChangedBefore Insulin-like growth factor-binding protein 7 (IGFBP7), tissue inhibitor of metalloproteinase 2 (TIMP-2), and neutrophil gelatinase-associated lipocalin (NGAL)Now tissue inhibitor of metalloproteinase 2 (TIMP-2)Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample
    • Addedneutrophil gelatinase-associated lipocalin (NGAL)Time frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample
    • AddedCystatin CTime frame: one hour prior to starting the race (baseline), immediately upon finishing the race (immediately post-race) and 24 from hours from the immediately post-race sample
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07519408
Collaborators
Western States Endurance Run Research Foundation
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Jun 27, 2026
Primary completion
Aug 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Bicarbonate

Start the discussion